Pub Date : 2025-01-23DOI: 10.1016/s2215-0366(24)00444-9
Anupa Anirudhan, Hansel Chris Rodrigues, Thomas Gregor Issac
No Abstract
{"title":"India's need for a national dementia policy","authors":"Anupa Anirudhan, Hansel Chris Rodrigues, Thomas Gregor Issac","doi":"10.1016/s2215-0366(24)00444-9","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00444-9","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"120 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1016/s2215-0366(24)00408-5
Limalemla Jamir, Ramyadarshni Vadivel, Sharad Philip
No Abstract
无摘要
{"title":"Gaps in crisis intervention: a global survey of suicide helplines","authors":"Limalemla Jamir, Ramyadarshni Vadivel, Sharad Philip","doi":"10.1016/s2215-0366(24)00408-5","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00408-5","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"15 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1016/s2215-0366(25)00004-5
Robson EM, Husin Mohamad H, Dashti SG, et al. Tracking the course of depressive and anxiety symptoms across adolescence (the CATS study): a population-based cohort study in Australia. Lancet Psychiatry 2024; published online Dec 4. https://doi.org/10.1016/S2215-0366(24)00361-4—In this Article, the author S Ghazaleh Dashti's name was misspelled and Mohamad Husin is the second author's surname. This correction has been made to the online version as of Jan 21, 2025, and will be made to the printed version.
{"title":"Correction to Lancet Psychiatry 2025; 12: 44–53","authors":"","doi":"10.1016/s2215-0366(25)00004-5","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00004-5","url":null,"abstract":"<em>Robson EM, Husin Mohamad H, Dashti SG, et al. Tracking the course of depressive and anxiety symptoms across adolescence (the CATS study): a population-based cohort study in Australia.</em> Lancet Psychiatry <em>2024; published online Dec 4. https://doi.org/10.1016/S2215-0366(24)00361-4</em>—In this Article, the author S Ghazaleh Dashti's name was misspelled and Mohamad Husin is the second author's surname. This correction has been made to the online version as of Jan 21, 2025, and will be made to the printed version.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"74 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1016/s2215-0366(24)00366-3
Heidi Taipale, Antti Tanskanen, Oliver Howes, Christoph U Correll, John M Kane, Jari Tiihonen
<h3>Background</h3>The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different treatment strategies used before and after the first relapse, and their associations with subsequent relapse risk.<h3>Methods</h3>In this population-based cohort study, we enrolled individuals (aged ≤45 years) with first-episode schizophrenia who were hospitalised and subsequently relapsed between 1996 and 2014 from the nationwide Finnish Hospital Discharge Register. Individuals who had not been taking antipsychotics within the year preceeding initial hospitalisation and who had a relapse within 5 years of discharge were included in the analyses. Treatment strategies were assessed during the 30 days before hospitalisation for the first relapse and 30 days after discharge and were categorised as either long-acting injectable, clozapine, non-clozapine oral antipsychotic monotherapy, non-clozapine oral antipsychotic polypharmacy, and antipsychotic non-use. Adjusted hazard ratios (aHRs) of the risk of second relapse based on treatment type were analysed with Cox regression models for 2 years after the first relapse, or until death or end of data linkage (Dec 31, 2017). People with lived experience of schizophrenia were not involved in the research and writing process.<h3>Findings</h3>Between Jan 31, 1996 and Dec 31, 2017, 3000 individuals had their first psychosis relapse and were eligible for analysis. Mean age was 30·0 years (SD 7·6), 1069 (35·6%) of patients were women and 1931 (64·4%) men. No ethnicity data were available. 2148 (71·7%) had a second relapse within 2 years. Before first relapse, most individuals were either not using antipsychotics (n=1366 [45·5%]), or were using non-clozapine oral antipsychotic monotherapy (n=973 [32·4%]). Compared with continuing the same treatment strategy used before the first relapse, switching to clozapine was associated with the lowest risk of second relapse compared with continuing any non-clozapine oral antipsychotic monotherapy (aHR 0·66, 95% CI 0·49–0·89; relapse rate 73·2% with oral non-clozapine antipsychotic monotherapy continuation <em>vs</em> 57·1% with switch to clozapine). Switching to another non-clozapine oral antipsychotic monotherapy (0·99, 0·76–1·28) was approximately as unhelpful in preventing the next relapse as switching to antipsychotic non-use (1·07, 0·80–1·42).<h3>Interpretation</h3>In patients with first-episode schizophrenia having their first psychosis relapse despite use of non-clozapine oral antipsychotics, continuation with the same antipsychotic modality or switch to another non-clozapine oral antipsychotic did not show evidence of being beneficial in relapse prevention, suggesting that clozapine should be started instead. This finding, together with existing knowledge of decreased risk of mortality associated with clozapine, challenges current treatment guidelines that recommend clozapine as a third-line tre
{"title":"Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study","authors":"Heidi Taipale, Antti Tanskanen, Oliver Howes, Christoph U Correll, John M Kane, Jari Tiihonen","doi":"10.1016/s2215-0366(24)00366-3","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00366-3","url":null,"abstract":"<h3>Background</h3>The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different treatment strategies used before and after the first relapse, and their associations with subsequent relapse risk.<h3>Methods</h3>In this population-based cohort study, we enrolled individuals (aged ≤45 years) with first-episode schizophrenia who were hospitalised and subsequently relapsed between 1996 and 2014 from the nationwide Finnish Hospital Discharge Register. Individuals who had not been taking antipsychotics within the year preceeding initial hospitalisation and who had a relapse within 5 years of discharge were included in the analyses. Treatment strategies were assessed during the 30 days before hospitalisation for the first relapse and 30 days after discharge and were categorised as either long-acting injectable, clozapine, non-clozapine oral antipsychotic monotherapy, non-clozapine oral antipsychotic polypharmacy, and antipsychotic non-use. Adjusted hazard ratios (aHRs) of the risk of second relapse based on treatment type were analysed with Cox regression models for 2 years after the first relapse, or until death or end of data linkage (Dec 31, 2017). People with lived experience of schizophrenia were not involved in the research and writing process.<h3>Findings</h3>Between Jan 31, 1996 and Dec 31, 2017, 3000 individuals had their first psychosis relapse and were eligible for analysis. Mean age was 30·0 years (SD 7·6), 1069 (35·6%) of patients were women and 1931 (64·4%) men. No ethnicity data were available. 2148 (71·7%) had a second relapse within 2 years. Before first relapse, most individuals were either not using antipsychotics (n=1366 [45·5%]), or were using non-clozapine oral antipsychotic monotherapy (n=973 [32·4%]). Compared with continuing the same treatment strategy used before the first relapse, switching to clozapine was associated with the lowest risk of second relapse compared with continuing any non-clozapine oral antipsychotic monotherapy (aHR 0·66, 95% CI 0·49–0·89; relapse rate 73·2% with oral non-clozapine antipsychotic monotherapy continuation <em>vs</em> 57·1% with switch to clozapine). Switching to another non-clozapine oral antipsychotic monotherapy (0·99, 0·76–1·28) was approximately as unhelpful in preventing the next relapse as switching to antipsychotic non-use (1·07, 0·80–1·42).<h3>Interpretation</h3>In patients with first-episode schizophrenia having their first psychosis relapse despite use of non-clozapine oral antipsychotics, continuation with the same antipsychotic modality or switch to another non-clozapine oral antipsychotic did not show evidence of being beneficial in relapse prevention, suggesting that clozapine should be started instead. This finding, together with existing knowledge of decreased risk of mortality associated with clozapine, challenges current treatment guidelines that recommend clozapine as a third-line tre","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"105 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1016/s2215-0366(24)00409-7
Siroos Mirzaei, Danuta Wasserman, Thomas G Schulze, Daniela Dörfler, Thomas Wenzel
No Abstract
没有抽象的
{"title":"Rejection of the hijab is not a psychiatric diagnosis","authors":"Siroos Mirzaei, Danuta Wasserman, Thomas G Schulze, Daniela Dörfler, Thomas Wenzel","doi":"10.1016/s2215-0366(24)00409-7","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00409-7","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"32 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1016/s2215-0366(24)00354-7
Gladson Vaghela, Le Van Truong, Vu Thi Thu Trang, Abdelrahman M Makram, I-Chun Hung, Mai Ngoc Luu, Nguyen Hai Nam, Randa Elsheikh, My Duc Thao Trieu, Le Thi Bich Trang, Zeeshan Khan, Cyril Nnaemeka Ikeanyionwu, Engy M Makram, Nguyen Tran Minh Duc, Minh-Hang Nguyen, Tan Weiling Amanda, Zia Baig, Karim Chafee, Shaimaa Yousry Fadel, Thuan Khac Nguyen, Nguyen Tien Huy
Background
Suicide helpline services (SHSs) are viewed as an essential part of suicide prevention. In the context of increased demand experienced by the services through the COVID-19 pandemic, as well as reduced funding, we aimed to evaluate such services to help assess their effectiveness and resilience.
Methods
This multinational cross-sectional survey, conducted from Sept 1, 2022, to Feb 28, 2023, evaluated SHSs in 150 countries. Local collaborators created an SHS directory, and a 42-question questionnaire was distributed via Survey Monkey through Find A Helpline and local collaborators. A team of experts, including individuals with lived experience, helped shape the research questions and study design. We did descriptive statistical analysis of answers to the questions, and data were further analysed using the Bayesian Model Averaging method to predict managers’ or supervisors’ low overall satisfaction with the service (MS-LOSS).
Findings
The study involved 446 responses from 105 countries for descriptive statistics. 354 (79·4%) of 446 services had insufficient funding, 249 (55·8%) had post-COVID-19 budget reductions, and 278 (62·3%) observed a sharp rise in suicide help requests during the COVID-19 pandemic. 420 responses were used for finding the optimal logistic model, which had an area under the curve of 0·679, indicating that pre-service training for volunteers was significantly associated with a reduction in MS-LOSS (odds ratio 0·16 [95% CI 0·07–0·31]; p<0·001), as was having a quality assurance structure (0·15 [0·02–0·70]; p=0·030). Higher MS-LOSS was associated with staff training only every 2–3 years instead of one or more times per year (2·87 [1·23–6·85], p=0.016) and with dilemmas with providing services in severe cases (1·68 [1·06–2·68]; p=0·028).
Interpretation
Global SHS reports indicate that both pre-task and ongoing training for volunteers and staff, coupled with a quality assurance structure, could decrease MS-LOSS. Our findings emphasise the need for training for volunteers, continuous training programmes for staff, and on-site support for individuals at risk of suicide.
{"title":"Evaluating the global landscape of suicide helpline services: a global survey across 105 countries","authors":"Gladson Vaghela, Le Van Truong, Vu Thi Thu Trang, Abdelrahman M Makram, I-Chun Hung, Mai Ngoc Luu, Nguyen Hai Nam, Randa Elsheikh, My Duc Thao Trieu, Le Thi Bich Trang, Zeeshan Khan, Cyril Nnaemeka Ikeanyionwu, Engy M Makram, Nguyen Tran Minh Duc, Minh-Hang Nguyen, Tan Weiling Amanda, Zia Baig, Karim Chafee, Shaimaa Yousry Fadel, Thuan Khac Nguyen, Nguyen Tien Huy","doi":"10.1016/s2215-0366(24)00354-7","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00354-7","url":null,"abstract":"<h3>Background</h3>Suicide helpline services (SHSs) are viewed as an essential part of suicide prevention. In the context of increased demand experienced by the services through the COVID-19 pandemic, as well as reduced funding, we aimed to evaluate such services to help assess their effectiveness and resilience.<h3>Methods</h3>This multinational cross-sectional survey, conducted from Sept 1, 2022, to Feb 28, 2023, evaluated SHSs in 150 countries. Local collaborators created an SHS directory, and a 42-question questionnaire was distributed via Survey Monkey through Find A Helpline and local collaborators. A team of experts, including individuals with lived experience, helped shape the research questions and study design. We did descriptive statistical analysis of answers to the questions, and data were further analysed using the Bayesian Model Averaging method to predict managers’ or supervisors’ low overall satisfaction with the service (MS-LOSS).<h3>Findings</h3>The study involved 446 responses from 105 countries for descriptive statistics. 354 (79·4%) of 446 services had insufficient funding, 249 (55·8%) had post-COVID-19 budget reductions, and 278 (62·3%) observed a sharp rise in suicide help requests during the COVID-19 pandemic. 420 responses were used for finding the optimal logistic model, which had an area under the curve of 0·679, indicating that pre-service training for volunteers was significantly associated with a reduction in MS-LOSS (odds ratio 0·16 [95% CI 0·07–0·31]; p<0·001), as was having a quality assurance structure (0·15 [0·02–0·70]; p=0·030). Higher MS-LOSS was associated with staff training only every 2–3 years instead of one or more times per year (2·87 [1·23–6·85], p=0.016) and with dilemmas with providing services in severe cases (1·68 [1·06–2·68]; p=0·028).<h3>Interpretation</h3>Global SHS reports indicate that both pre-task and ongoing training for volunteers and staff, coupled with a quality assurance structure, could decrease MS-LOSS. Our findings emphasise the need for training for volunteers, continuous training programmes for staff, and on-site support for individuals at risk of suicide.<h3>Funding</h3>RSTMH Small Grants Award 2021, UK NIHR, and MEXT.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"32 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1016/s2215-0366(24)00376-6
Niamh Molloy, Imogen Kilcoyne, Hannah Belcher, Til Wykes
People with lived experience of mental health difficulties have highlighted that research outcomes do not capture issues they feel are important. This mismatch might affect the validity of trials, such that beneficial effects could be missed or results could be counted as a benefit when they are not. Co-development of patient-reported outcome measures ensures patient perspectives are captured adequately. To identify mental health outcome measures that meet a strict definition of being co-developed and to describe the methods and quantity of involvement at each pre-defined stage of measure co-development, we searched five electronic databases (MEDLINE, Web of Science, Scopus, PsycINFO, and Embase) for relevant papers, alongside a search of the non-peer reviewed literature and handsearching. The study was registered on PROSPERO (CRD42024520941). Retrieved papers were independently screened and quality was assessed following PRISMA guidelines. Extracted data were synthesised narratively. The search identified 23 mental health outcome measures from 34 papers. The most frequent types of involvement to co-develop outcomes were service-user researchers and lived experience groups as advisors undertaking activities such as leading qualitative exercises, but there were gaps. Many benefits were reported such as increased relevancy and acceptability of the measures. Based on these findings, recommendations for methods and a novel scale for judging quantity of involvement for co-development were identified, but challenges for co-development remain. The reviewed papers show that co-development is possible and could provide more relevant and meaningful outcomes for clinical practice and research.
{"title":"Exploring the involvement of people with lived experience of mental disorders in co-developing outcome measures: a systematic review","authors":"Niamh Molloy, Imogen Kilcoyne, Hannah Belcher, Til Wykes","doi":"10.1016/s2215-0366(24)00376-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00376-6","url":null,"abstract":"People with lived experience of mental health difficulties have highlighted that research outcomes do not capture issues they feel are important. This mismatch might affect the validity of trials, such that beneficial effects could be missed or results could be counted as a benefit when they are not. Co-development of patient-reported outcome measures ensures patient perspectives are captured adequately. To identify mental health outcome measures that meet a strict definition of being co-developed and to describe the methods and quantity of involvement at each pre-defined stage of measure co-development, we searched five electronic databases (MEDLINE, Web of Science, Scopus, PsycINFO, and Embase) for relevant papers, alongside a search of the non-peer reviewed literature and handsearching. The study was registered on PROSPERO (CRD42024520941). Retrieved papers were independently screened and quality was assessed following PRISMA guidelines. Extracted data were synthesised narratively. The search identified 23 mental health outcome measures from 34 papers. The most frequent types of involvement to co-develop outcomes were service-user researchers and lived experience groups as advisors undertaking activities such as leading qualitative exercises, but there were gaps. Many benefits were reported such as increased relevancy and acceptability of the measures. Based on these findings, recommendations for methods and a novel scale for judging quantity of involvement for co-development were identified, but challenges for co-development remain. The reviewed papers show that co-development is possible and could provide more relevant and meaningful outcomes for clinical practice and research.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"11 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：